Pure Global AI
NCT06260722Recruiting

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Eli Lilly and CompanyPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Diabetes Mellitus, Type 2
Drug/Device/Intervention
Retatrutide
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Eli Lilly and Company
Location
Birmingham,Escondido,Long Beach,Northridge,Rancho Cucamonga,Aurora,Daytona Beach,Miami,Miramar,Winter Haven,Suwanee,Woodstock,Honolulu,Idaho Falls,Newburgh,Monroe,Hyattsville,Boston,Fall River,Troy,La, Argentina,Canada,Mexico,Puerto Rico,United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Feb 21, 2024
End date
Mar 30, 2027
Enrollment
1250 participants
Primary outcome

Change from Baseline in Hemoglobin A1c (HbA1c) (%)

Summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared
 with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with
 metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will
 last about 26 months and may include up to 24 visits.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06260722
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06260722 through Pure Global AI's free database. This Phase 3 trial is sponsored by Eli Lilly and Company and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 1250 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.